Robert Califf Net Worth

Robert Califf biography

Robert M. Califf is Independent Director of the Company. Dr. Califf has served as a member of our Board of Directors since February 2018. Dr. Califf is Head of Strategy and Policy for Verily Life Sciences and Google Health, divisions of Google’s parent company Alphabet Inc. He is an adjunct professor in the Duke University School of Medicine, where he previously served as the Vice Chancellor for Health Data Science at Duke Health and Director of the Duke University Center for Health Data Science, and an adjunct professor in the Department of Medicine at Stanford University. Dr. Califf served as Commissioner of the United States Food and Drug Administration (FDA) between February 2016 and January 2017, and as Deputy Commissioner of the FDA’s Office of Medical Products and Tobacco from January 2015 until his appointment as FDA Commissioner. Prior to joining the FDA, Dr. Califf was Professor of Medicine and Vice Chancellor for Clinical and Translational Research at Duke University. He also served as Director of the Duke Translational Medicine Institute and founding Director of the Duke Clinical Research Institute. Dr. Califf is a member of the National Academy of Medicine (NAM) and has served on various committees for the NAM. He has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees Drfor the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging. Dr. Califf held leadership positions and board appointments for biopharmaceutical companies including Portola Pharmaceuticals, Inc., Proventus AB and Nitrox, LLC. Dr. Califf received his medical degree from the Duke University School of Medicine in Durham, North Carolina and completed his residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke University.

What is the salary of Robert Califf?

As the Independent Director of Cytokinetics Inc, the total compensation of Robert Califf at Cytokinetics Inc is $181,110. There are 17 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.

How old is Robert Califf?

Robert Califf is 68, he's been the Independent Director of Cytokinetics Inc since 2018. There are 6 older and 14 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.

What's Robert Califf's mailing address?

Robert's mailing address filed with the SEC is 280, East Grand Avenue, South San Francisco, San Mateo County, California, 94080, United States.

Insiders trading at Cytokinetics Inc

Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi..., and Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.

What does Cytokinetics Inc do?

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Cytokinetics Inc executives and stock owners

Cytokinetics Inc executives and other stock owners filed with the SEC include:

• Robert Blum,
  President, Chief Executive Officer, Director
• Fady Malik,
  Executive Vice President - Research and Development
• Mark Schlossberg,
  Senior Vice President, General Counsel, Secretary
• Ching Jaw,
  Chief Financial Officer, Senior Vice President
• David Cragg,
  Chief Human Resource Officer, Chief Administrative Officer
• Robert I. Blum,
  CEO, Pres & Director
• Dr. Fady Ibraham Malik,
  Exec. VP of R&D
• Mark A. Schlossberg,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Ching W. Jaw,
  Sr. VP & CFO
• David W. Cragg,
  Chief HR & Admin. Officer
• Leonard Patrick Gage,
  Independent Chairman of the Board
• Wendall Wierenga,
  Independent Director
• B. Lynne Parshall,
  Independent Director
• John Henderson,
  Independent Director
• Santo Costa,
  Independent Director
• Sandford Smith,
  Independent Director
• Edward Kaye,
  Independent Director
• Robert Califf,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Diane Weiser,
  IR Contact Officer
• Robert Wong,
  Chief Accounting Officer, Vice President
• Kari K. Loeser J.D.,
  VP & Chief Compliance Officer
• Robert Wong,
  VP & Chief Accounting Officer
• Jeff Lotz,
  VP of Sales & Operations
• Dr. James A. Spudich Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Bradley Paul Morgan,
  SVP Drug Discovery & Early Dev
• Caryn Gordon Mc Dowell,
  GC & Chief Compliance Officer
• Elisabeth Schnieders,
  Sr. VP, Business Development
• L Patrick Gage,
  Director
• Bonnie Charpentier,
  SVP Regulatory & Compliance
• Robert Arthur Harrington,
  Director
• Associates Vi Lp Srb,
  10% owner
• Sung Lee,
  EVP, Chief Financial Officer
• Peter S Roddy,
  SVP Finance & CAO
• Muna Bhanji,
  Director
• Michael Rabson,
  SVP Business Dev/Legal & GC
• A Grant Iii Heidrich,
  Director
• Mark Mcdade,
  Director
• Brett A Pletcher,
  EVP, Chief Legal Officer
• Sharon Barbari,
  Sr. VP, Finance & CFO
• Charles J Homcy,
  Director
• James H Sabry,
  President and CEO
• David J Jr Morgans,
  SVP-Drug Discovery and Dev
• James A Spudich,
  Director
• Michael Schmertzler,
  Director
• Jay K Trautman,
  VP, Technology
• Stephen M Dow,
  Director
• Denise Gilbert,
  Director
• Capital Ltd Portfolio Servi...,
  
• Suisse First Boston/Credit ...,
  
• John Vdomenik Stephen Lbayl...,
  
• William J Rutter,
  Director
• Ixmayfield Ix Management Ll...,
  
• Rosen Vii Affiliates Fund L...,
  10% owner
• Associates Vii Lp Srb,
  10% owner
• Associates Viii Lp Srb,
  10% owner
• Rosen Viii Affiliates Fund ...,
  10% owner
• Rosen Fund Viii Lp Sevin,
  10% owner
• Rosen Fund Vi Lp Sevin,
  10% owner
• Rosen Fund Vii Lp Sevin,
  10% owner
• Rosen Vi Affiliates Fund Lp...,
  10% owner
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Andrew Callos,
  EVP, Chief Commercial Officer